There were 1,936 press releases posted in the last 24 hours and 443,006 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Opinion/decision on a Paediatric investigation plan (PIP): Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510), decision type: , therapeutic area: , PIP number: P/0261/2022

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image